Prime Therapeutics Expanding Formulary Exclusion Program In 2018
Executive Summary
The NetResults formulary contributed to a 0.2% decline in overall drug spending by the pharmacy benefit manager's commercial clients in 2017, according to Prime Therapeutics' Drug Trend report.
You may also be interested in...
Lilly's Basaglar, Crestor Generics Helped Hold Down Drug Spending Growth In 2017
Express Scripts' annual drug trend report highlights impact of key follow-on launches, and its own management solutions programs, in limiting the growth in overall drug spending for commercial plans to 1.5%; forecast calls for double-digit growth in inflammatory category to continue at least the next three years until biosimilar savings kick in.
CVS 2018 Formulary: Outcomes-Based Contracts In Oncology, Obesity, COPD
And for diabetes, Jardiance is out and Invokana is in; CVS formulary update includes far fewer exclusions than previous years and reinstates coverage for several drugs, signaling more muted approach to management.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.